MONTGOMERY, Ala.--(BUSINESS WIRE)--ProEthic Pharmaceuticals, Inc., today announced that it has entered into a definitive licensing and distribution agreement with Cipher Pharmaceuticals, Inc. (TSX: DND), under which Cipher has granted ProEthic the exclusive right to market, sell and distribute Lipofen™ in the United States, its territories and possessions. Lipofen is a novel, patented formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia, a cholesterol disorder.
